/
CGEN
$2.16+$0.07 (+3.35%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$197.7M
95M shares
52-week range
$1.30 – $3.24
45% from low
Exchange
NASDAQ
CS
Borrow rate
0.68%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-5.84
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.8M | $0 | $2.0M | $6.0M | $7.5M | $33.5M | $27.9M | $72.8M |
| Cost of revenue | $1.0M | $989.0K | $60.0K | $680.0K | $975.0K | $2.0M | $7.9M | $9.3M |
| Gross profit | $16.8M | −$989.0K | $1.9M | $5.3M | $6.5M | $31.5M | $19.9M | $63.5M |
| Gross margin | 94.2% | — | 97.0% | 88.7% | 87.0% | 94.0% | 71.5% | 87.3% |
| R&D | $30.3M | $19.8M | $22.8M | $28.7M | $30.6M | $34.5M | $24.8M | $22.8M |
| Operating income | −$23.2M | −$28.9M | −$31.5M | −$35.1M | −$35.4M | −$13.0M | −$14.9M | $31.3M |
| EBITDA | −$21.8M | −$27.0M | −$28.9M | −$33.7M | −$33.1M | −$9.3M | −$9.2M | $35.9M |
| Net income | −$22.6M | −$27.3M | −$29.7M | −$34.2M | −$33.7M | −$18.8M | −$14.2M | $35.3M |
| Net margin | -127.0% | — | -1484.9% | -570.0% | -449.3% | -56.1% | -51.1% | 48.6% |
| EPS (diluted) | -0.41 | -0.43 | -0.37 | -0.41 | -0.39 | -0.21 | -0.16 | 0.38 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $9M | $-0.29 | $-0.39–$-0.18 | 3 |
| 2027 | $16M | $-0.29 | $-0.57–$0.15 | 3 |
| 2028 | $31M | $-0.26 | $-0.27–$-0.26 | 5 |
| 2029 | $27M | $-0.38 | $-0.65–$-0.12 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Compugen Ltd
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
www.cgen.com- Employees
- 75
- IPO / List date
- Aug 11, 2000
Held by traders on TradeandTell
No one on the platform currently holds CGEN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CGEN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CGEN yet.
